E-resources
-
Spiegel, Jay Y; Patel, Shabnum; Muffly, Lori; Hossain, Nasheed M; Oak, Jean; Baird, John H; Frank, Matthew J; Shiraz, Parveen; Sahaf, Bita; Craig, Juliana; Iglesias, Maria; Younes, Sheren; Natkunam, Yasodha; Ozawa, Michael G; Yang, Eric; Tamaresis, John; Chinnasamy, Harshini; Ehlinger, Zach; Reynolds, Warren; Lynn, Rachel; Rotiroti, Maria Caterina; Gkitsas, Nikolaos; Arai, Sally; Johnston, Laura; Lowsky, Robert; Majzner, Robbie G; Meyer, Everett; Negrin, Robert S; Rezvani, Andrew R; Sidana, Surbhi; Shizuru, Judith; Weng, Wen-Kai; Mullins, Chelsea; Jacob, Allison; Kirsch, Ilan; Bazzano, Magali; Zhou, Jing; Mackay, Sean; Bornheimer, Scott J; Schultz, Liora; Ramakrishna, Sneha; Davis, Kara L; Kong, Katherine A; Shah, Nirali N; Qin, Haiying; Fry, Terry; Feldman, Steven; Mackall, Crystal L; Miklos, David B
Nature medicine, 08/2021, Volume: 27, Issue: 8Journal Article
Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19 or CD19 disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial ( NCT03233854 ) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19 in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22 disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.